Your computer can help scientists search for new childhood cancer treatments

IBMMedical researchers and IBM (NYSE: IBM) are asking the public's help in finding prospective treatments for childhood cancers, the top worldwide cause of death by disease for children. Scientists are searching for chemical drug candidates that can affect the key molecules and proteins that control cancer cells in several common childhood cancers. However, finding drug candidates is an expensive and slow process.

To accelerate the process and broaden the search, IBM is providing those scientists free access to World Community Grid, an IBM-funded and managed program which advances scientific research by harnessing computing power "donated" by volunteers around the globe. This resource is the equivalent of a free, virtual supercomputer that enables scientists to more quickly conduct millions of virtual experiments to help pinpoint promising drug candidates for further study.

The project was announced in the United States at a press conference led by Connecticut Governor Dannel Malloy, IBM, and Dr. Ching Lau of Connecticut Children’s Medical Center, Jackson Laboratory and UConn School of Medicine, who is spearheading this crowdsourced research effort in the US.

Volunteers don't provide any time, money or technical expertise to assist with this research effort, called Smash Childhood Cancer. Instead, they participate in World Community Grid by downloading and installing a free, secure app on their computer or Android devices. While otherwise idle, volunteers' devices automatically perform virtual experiments on behalf of the research team. The results are transmitted back to researchers, where they are analyzed.

Smash Childhood Cancer brings together an international team of expert researchers from Chiba University and Kyoto University in Japan; The University of Hong Kong in Hong Kong; and the Connecticut Children's Medical Center, the Jackson Laboratory, and the University of Connecticut School of Medicine in the United States.

The global initiative is led by Dr. Akira Nakagawara, an internationally renowned pediatric oncologist, molecular biologist and CEO of the Saga Medical Center KOSEIKAN, in Japan. Dr. Nakagawara used the same research approach on a previous World Community Grid project which successfully identified drug candidates for neuroblastoma, one of the most common cancers in children.

Smash Childhood Cancer expands the search for treatments for neuroblastoma, as well as other forms of childhood cancers including brain tumor, Wilms’ tumor (tumor of the kidney), germ cell tumors (which impact the reproductive and central nervous system), hepatoblastoma (cancer of the liver) and osteosarcoma (cancer of the bone).

Since 2004, IBM’s award-winning World Community Grid has provided this resource for 27 research projects in critical areas including cancer, HIV/AIDS, Zika and Ebola viruses, genetic mapping, sustainable energy, clean water, and ecosystem preservation.

To date, World Community Grid has connected researchers to half a billion U.S. dollars' worth of free supercomputing power. This resource to accelerate scientific discovery, partially hosted in IBM's cloud, has been fueled by 720,000 individuals and 440 institutions from 80 countries who have have donated more than 1 million years of computing time on over 3 million desktops, laptops and Android mobile devices. Their participation has helped identify potential treatments for childhood cancer, more efficient solar cells, and more efficient water filtration materials.

World Community Grid is enabled by Berkeley Open Infrastructure for Network Computing (BOINC), an open source software platform developed at the University of California, Berkeley.

Join World Community Grid today to enable your computer or Android device to help Smash Childhood Cancer.

For further information, please visit:
https://www.worldcommunitygrid.org

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Brilinta significantly reduces CV events and coron…

AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV dea...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

How old antibiotic compounds could become tomorrow…

As the fight against drug-resistant infections continues, University of Leeds scientists are looking back at previously discarded chemical compounds, to see if any could ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]